Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors - Wikidata - awgldk - TriplyDB

Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors

Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors

http://www.wikidata.org/entity/Q24614112

about

Targeting LKB1 in cancer - exposing and exploiting vulnerabilities Predictive biomarkers in precision medicine and drug development against lung cancer Targeted therapies in development for non-small cell lung cancer Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR CAS proteins in health and disease: an update Regulation of SRC family kinases in human cancers Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition Novel insights into the molecular origins and treatment of lung cancer Role of ABL family kinases in cancer: from leukaemia to solid tumours Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer LKB1 loss in melanoma disrupts directional migration toward extracellular matrix cues.Reconstructing targetable pathways in lung cancer by integrating diverse omics data Data-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells.Structural interrogation of phosphoproteome identified by mass spectrometry reveals allowed and disallowed regions of phosphoconformation.Liver kinase B1 regulates the centrosome via PLK1.Minichromosome maintenance protein 2 and 3 promote osteosarcoma progression via DHX9 and predict poor patient prognosis.Molecular pathways and therapeutic targets in lung cancer Systems biology approaches to develop innovative strategies for lung cancer therapy.The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer An AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls Snail1 and metastatic potential.Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer.Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes Integrating phosphoproteomics in systems biology.Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers The LKB1 tumor suppressor as a biomarker in mouse and human tissues.Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers Inositol pyrophosphates promote tumor growth and metastasis by antagonizing liver kinase B1

P2860

Q26801412-380F4199-3356-4202-B7EC-51E9C0F4D51F Q26824536-CB84BAB2-6A6A-48D5-AEDF-94331B311C78 Q27022852-64D0FF20-B6D9-4914-AA8B-8EC632B6EA0C Q27345462-EB0B3497-4ADA-4239-A410-DA609FFA1F44 Q27851633-B488182A-B555-452D-9033-849C470F8E9E Q27851674-6E648B28-CDB4-4AEE-BF37-D6E70BDA3942 Q27851728-C8E378A4-0D54-4CA1-AEEC-0D95BD5AE8A2 Q27853005-580565CA-F9BF-43BD-AC39-D0D769F02924 Q28085339-2323BD42-5594-4571-A70D-73472D2ADF24 Q28086993-3A985024-0D69-4801-9A8D-9138437925CC Q28242737-8ACD8B37-1F1D-4515-985B-350412C5FBE6 Q28243770-B44F95F0-3DE8-4C62-A2DF-101A1A3093AD Q28250096-5E3FF452-011B-423F-BC01-167EAFE2BAAA Q28260541-3049456B-B7F1-43F6-A652-71F9AA58FCCA Q28301135-369242BA-AEC2-4F6D-AC1A-F6FEAAF117F7 Q28386773-844C1084-4018-429F-8F0D-F62C3BC43815 Q28396643-00FD91D1-F5AE-4717-BB7E-DDD1C1D21389 Q28730029-390B4676-4E0F-4F5E-A222-3D0754A82619 Q30425261-8A449EF4-75EE-4278-B5E1-28FC516E3382 Q30596293-A28BD4BE-22EF-49D2-8544-F4B6BE2AD256 Q30679547-927E1841-8F76-449B-A638-00C47792FCBA Q31171102-3DB149DF-98B6-4454-B791-01475079000B Q33557129-AD3DFD02-7C61-46FE-BABE-6840E059DBC2 Q33654208-0190DCFB-A8C4-44E3-95F5-F0F255BAD2C3 Q33688672-609D41E1-21C1-44C0-A91C-80831D4147B0 Q33688872-9AF47CAF-B6F9-4F3E-BD6F-2A744EA5CF7B Q33720233-AE23A995-DB5F-4D41-A786-AD4D53E8D602 Q34048907-B4D97756-D01E-4F9E-9F42-D40D6411C29F Q34117181-7EBF7718-F8E9-460B-9EB6-27C387F16B55 Q34163579-96B34547-5B48-4A69-9B74-F1BAE003C38D Q34258933-C8017AE6-2061-46DD-AB61-0BA2479C66D6 Q34295621-DE51FBAA-CAE3-4B6C-BBA1-4616EED3B6F5 Q34374191-573A6E2E-23BF-4317-9D6E-29A0FE37B60D Q34377093-58A8F9D2-2D32-4E1E-B171-1120452F7677 Q34593929-C774B251-4AD2-4E90-9977-93C9B01CE7C1 Q34880376-057950AD-B456-4E38-BAAF-3501BAA4E65E Q34899298-1EBF56EE-0EE9-46E5-9A77-59FF742A57A8 Q35004753-55C0F9E4-39B7-4A7F-9B15-C93F72B6F1F1 Q35051540-ECBD4D65-9835-404A-8B74-83ACC7FE41C3 Q35090038-213E7823-2D13-4E04-8FAA-48245F0DE90C

P2860

Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors

http://www.wikidata.org/entity/Q24614112

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Integrative genomic and proteo ...... ficient metastatic lung tumors

@ast

Integrative genomic and proteo ...... ficient metastatic lung tumors

@en

Integrative genomic and proteo ...... ficient metastatic lung tumors

@nl

type

label

Integrative genomic and proteo ...... ficient metastatic lung tumors

@ast

Integrative genomic and proteo ...... ficient metastatic lung tumors

@en

Integrative genomic and proteo ...... ficient metastatic lung tumors

@nl

prefLabel

Integrative genomic and proteo ...... ficient metastatic lung tumors

@ast

Integrative genomic and proteo ...... ficient metastatic lung tumors

@en

Integrative genomic and proteo ...... ficient metastatic lung tumors

@nl

P1433

Q24614112-92B1E601-CFC7-4540-BE78-FCDD5A905565

P1476

Q24614112-0CDA7671-B350-44DC-9571-87EC377E593B

P2093

Q24614112-06DD7ECD-9B00-4A59-B3D4-4A68567F3B5E

Q24614112-143CB8DD-5F05-4568-9E80-277E6865C1DF

Q24614112-183EDFD3-C005-4199-B0BE-60080D1EAD9C

Q24614112-2C8F4788-8F0D-4DCE-A61E-100BA7B1B6B1

Q24614112-367F0210-367D-4BBC-B128-0F8656C46DBC

Q24614112-596C2927-3997-47AF-8127-D89E8B1F3087

Q24614112-71F57FBC-5828-4C16-B44B-9BD94D338965

Q24614112-7BDA7E50-9194-42FB-A9E4-EF2523BA2582

Q24614112-8CC6E580-2CB9-4791-8F2B-05F1CAB69C9A

Q24614112-8E20AEEB-0AE4-45A2-AD53-2DD1C24C084B

P2860

Q24614112-02FB2142-D117-474B-A0CA-4096149AA510

Q24614112-098389F5-261B-4CDD-9767-47CBE4C0C449

Q24614112-0A17C1D7-D5AF-41B0-82B7-7939F19AE6E8

Q24614112-190A18CD-9310-4FC1-83BF-319FA8EFEE92

Q24614112-1B221AF9-E40D-4573-9763-A814D01F67BF

Q24614112-38D5EFAB-429C-4D98-A296-D2C267FA4BB2

Q24614112-3C8BB114-D882-451B-8985-EF64930D6D6F

Q24614112-3F5BDE5A-4C7E-42E9-8855-1EC818EC7D60

Q24614112-3FAE68F8-58CB-4A9E-967A-20CD987B7188

Q24614112-4D163763-69F6-4282-975D-06CAEF94B2E4

P304

Q24614112-CC517394-C435-41CE-ACB3-1A4B9DBE0560

P31

Q24614112-54BEFB31-3F2A-4C64-881D-F41E76F29CAA

P3181

Q24614112-DB303FCE-C0F5-4783-AB43-710C2DF3FC28

P356

Q24614112-D5E6FA65-BFC1-48E4-9052-5169D3B9EB76

P407

Q24614112-1A2CAA60-2480-4388-B2AD-B99213BA0A02

P433

Q24614112-9636E7CC-94B4-4E9A-B63A-CEE0DE9F6F11

P478

Q24614112-B189D114-F4B2-4F11-A238-85B641BD239E

P50

Q24614112-028EC181-57C8-4A15-A43E-C80DB13E8296

Q24614112-5FBE106A-6B72-491E-A22E-8A31C86B6FEF

Q24614112-60AEC8B4-6F44-431B-9A92-F4C25D0B0C9F

Q24614112-94AC3D1D-B8A1-4085-A971-6D307C1C1B87

P577

Q24614112-80C3C2AE-FF4B-4C07-9D3F-A2572A9DA1BD

P5875

Q24614112-7074D845-5AAE-4664-A009-8230E91F2C54

P698

Q24614112-D9D7AC81-DB18-42B7-92D1-A4A4F6FEF639

P921

Q24614112-A594B6D7-1203-4A66-A47B-335223970570

P932

Q24614112-D03C08EF-DEE1-4EA5-8BFB-782C886FBD1B

P3181

P356

J.CCR.2010.04.026

P1433

P1476

Integrative genomic and proteo ...... ficient metastatic lung tumors

@en

P2093

Autumn L Jackson

http://www.w3.org/2001/XMLSchema#string

Benjamin A Sanofsky

http://www.w3.org/2001/XMLSchema#string

Carla F Kim

http://www.w3.org/2001/XMLSchema#string

Carlos García-Echeverría

http://www.w3.org/2001/XMLSchema#string

Christa L Borgman

http://www.w3.org/2001/XMLSchema#string

Diego H Castrillon

http://www.w3.org/2001/XMLSchema#string

Geoffrey I Shapiro

http://www.w3.org/2001/XMLSchema#string

Hongbin Ji

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

Jeffrey C Silva

http://www.w3.org/2001/XMLSchema#string

P2860

Integrin-regulated FAK-Src signaling in normal and cancer cells

WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

The basics of epithelial-mesenchymal transition

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung

Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene

The LKB1 tumor suppressor negatively regulates mTOR signaling

Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis

P304

547-559

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4889929

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CCR.2010.04.026

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Norman Sharpless

Julian Carretero

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44667080

http://www.w3.org/2001/XMLSchema#string

P698

20541700

http://www.w3.org/2001/XMLSchema#string

P921

P932

2901842

http://www.w3.org/2001/XMLSchema#string